Sangamo BioSciences CFO Unloads $112,800 in Stock (SGMO)
Sangamo BioSciences (NASDAQ:SGMO) CFO Henry Ward Wolff sold 10,000 shares of Sangamo BioSciences stock on the open market in a transaction dated Thursday, October 10th. The stock was sold at an average price of $11.28, for a total value of $112,800.00. Following the completion of the sale, the chief financial officer now directly owns 209,219 shares of the company’s stock, valued at approximately $2,359,990. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on SGMO shares. Analysts at Thomson Reuters/Verus upgraded shares of Sangamo BioSciences from a “sell” rating to a “hold” rating in a research note to investors on Monday. Analysts at Zacks upgraded shares of Sangamo BioSciences from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, July 30th. They now have a $10.50 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $16.70.
Shares of Sangamo BioSciences (NASDAQ:SGMO) traded down 0.62% during mid-day trading on Tuesday, hitting $11.28. The stock had a trading volume of 806,472 shares. Sangamo BioSciences has a one year low of $4.92 and a one year high of $13.20. The stock’s 50-day moving average is $10.88 and its 200-day moving average is $9.51. The company’s market cap is $610.3 million.
Sangamo BioSciences (NASDAQ:SGMO) last posted its quarterly earnings results on Wednesday, July 24th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. The company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $4.77 million. During the same quarter in the previous year, the company posted ($0.11) earnings per share. The company’s revenue for the quarter was up 50.0% on a year-over-year basis. Analysts expect that Sangamo BioSciences will post $-0.43 EPS for the current fiscal year.
Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.